# US 2021/0330721 A1 · High potency stable formulations of vaginal lactobacillus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330721 A1
- Document ID: US20210330721A1
- Status: Published application
- Kind: A1
- Application number: 17/372,325
- Filed: 2021-07-09
- Published: 2021-10-28
- Earliest claimed: 2017-07-07
- Assignees: Osel, Inc.
- Applicants: Osel, Inc.
- Inventors: Thomas P. Parks; Angela Marcobal
- Web page: https://patentgrep.com/patent/US20210330721A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 15/02: for disorders of the vagina
- A61P 31/04: Antibacterial agents
- C12N 1/04: Preserving or maintaining viable microorganisms (immobilised microorganisms C12N11/00)
- C12N 1/20: Bacteria; Culture media therefor
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention provides for a dry preserved formulation of Lactobacillus suitable for administration to people as a pro-biotic or live biotherapeutic treatment where the formulation is stable, has high potency, and contains no animal-derived excipients.

## Claims

### Claim 1

An aqueous bacterial suspension of vaginal Lactobacillus species, having no animal-derived excipients, where the suspension results from a combination of a cell pellet of vaginal Lactobacillus species with an aqueous preservation medium consisting essentially of:
(i) trehalose at between 5-20%, w/v;
(ii) xylitol at between 2-9%, w/v;
(iii) sodium ascorbate 0.5-1.5%, w/v; and
(iv) sodium phosphate at between 10-50 mM.

### Claim 2 (depends on 1)

The bacterial suspension of claim 1, wherein the aqueous preservation medium optionally further comprises sodium glutamate at between 0-5%.

### Claim 3 (depends on 1)

The bacterial suspension of claim 1, wherein the vaginal Lactobacillus species has the ability to produce greater than 0.5 ppm of hydrogen peroxide under effective culture conditions.

### Claim 4 (depends on 1)

The bacterial suspension of claim 1, wherein the vaginal Lactobacillus species is selected from the group consisting of Lactobacillus crispatus, Lactobacillus jensenii and Lactobacillus gasseri.

### Claim 5 (depends on 1)

The bacterial suspension of claim 1, wherein the aqueous preservation medium consists essentially of:
(i) trehalose at between 5-15%, w/v;
(ii) xylitol at between 2-7%, w/v;
(iii) sodium ascorbate 0.5-1.0%, w/v; and
(iv) sodium phosphate at between 10-30 mM.

### Claim 6 (depends on 5)

The bacterial suspension of claim 5, wherein the aqueous preservation medium optionally further comprises sodium glutamate at between 0-5%.

### Claim 7 (depends on 1)

A dry powder obtained by lyophilizing the bacterial suspension of claim 1.

### Claim 8 (depends on 7)

The dry powder of claim 7, wherein the powder has a water activity value of less than 0.220.

### Claim 9 (depends on 8)

The dry powder of claim 8, wherein the powder is combined with an inactive excipient at a ratio of powder: excipient of between 1:1 and 1:10 w/w.

### Claim 10 (depends on 9)

The dry powder of claim 9, wherein the excipient is maltodextrin.

### Claim 11 (depends on 9)

The dry powder of claim 9, wherein the ratio of powder: excipient is between 1:1 and 1:5 w/w.

### Claim 12 (depends on 7)

The dry powder of claim 7, wherein the powder is contained within a plastic housing designed for vaginal administration.

### Claim 13

A method of preserving Lactobacillus spp. under dry conditions without animal-derived excipients, the method comprising:
(i) obtaining an aqueous suspension of vaginal Lactobacillus species having a cell concentration between 108 to 1013 per ml;
(ii) centrifuging the solution to form a bacterial cell pellet; and
(iii) resuspending the bacterial cell pellet in an aqueous preservation medium consisting essentially of:
(a) trehalose at between 5-20%, w/v;
(b) xylitol at between 2-9%, w/v;
(c) sodium ascorbate 0.5-1.5%, w/v; and
(d) sodium phosphate at between 10-50 mM;
where the weight ratio of cell pellet wet weight (grams) to preservation media (mL) is between 1:1 and 1:5 grams of cell pellet to milliliter of preservation media to yield a bacterial suspension.

### Claim 14 (depends on 13)

The method of claim 13, wherein the bacterial suspension is lyophilized to yield a dry powder.

### Claim 15 (depends on 7)

A method of treating abnormal vaginal microbiota in a woman comprising the steps of:
(i) selecting a woman having a diagnosis of abnormal vaginal microbiota;
(ii) administering to the woman an antibiotic in an amount effective to reduce the level of abnormal vaginal microbiota;
(iii) following step (ii), administering to the woman by vaginal administration the dry powder of claim 7.

### Claim 16 (depends on 15)

The method of claim 15, wherein step (ii) includes daily administration of antibiotic for between 2 and 7 days and wherein step (iii) begins at any time between two days before the completion of antibiotic administration and two days after the administration of antibiotic in step (ii) ends.

### Claim 17 (depends on 15)

The method of claim 15, wherein the vaginal Lactobacillus species is selected from the group consisting of Lactobacillus crispatus, Lactobacillus jensenii, and Lactobacillus gasseri.

### Claim 18 (depends on 15)

The method of claim 15, wherein the dry powder is combined with an inactive excipient at a ratio of powder: excipient of between 1:1 and 1:10 w/w.

### Claim 19 (depends on 18)

The method of claim 18, wherein the excipient is maltodextrin.

### Claim 20 (depends on 15)

The method of claim 15, wherein the antibiotic is clindamycin, metronidazole, or tinidazole.
